STINGing the Tumor's immune evasion mechanism

Abstract

In order to enhance the STING dependent type I interferon (IFN) response, we formulated cyclic dinucleotides (CDN) with cancer vaccines to develop STINGVAX. Interestingly, tumors from STINGVAX treated mice demonstrated dramatic PD-L1 upregulation. When combined with PD-1 blockade, STINGVAX induced regression of established tumors that did not respond to PD-1 blockade alone.

Keywords

• adjuvants
• cyclic dinucleotides
• cancer vaccines
• cancer vaccine
• sting
• tumor microenvironment
• t-cells